OncLive SOSS

Authors

Carl M. Gay, MD, PhD

Latest:

SCLC: Future Therapies and Advice to Community Oncologists

Drs Carl M. Gay and Jared Weiss highlight several novel strategies that show promise in optimizing treatment for patients with small cell lung cancer and respond to questions from community oncologists who manage treatment for patients with lung cancer.

Stephan Stilgenbauer, MD, Ulm University

Latest:

Novel Treatment Combinations in Chronic Lymphocytic Leukemia

Dr Brown and Dr Stilgenbauer provide their input on novel treatment options emerging for chronic lymphocytic leukemia.

Rutika J. Mehta, MD, MPH

Latest:

Dr. Mehta on the Current Treatment Paradigm in HER2-Positive Gastric Cancer

Rutika J. Mehta, MD, MPH, discusses the current treatment paradigm in HER2-positive gastric cancer.

Tracy T. Batchelor, MD, MPH

Latest:

Dr Batchelor on the Rationale for Investigating Tirabrutinib in PCNSL

Tracy T. Batchelor, MD, MPH, discusses the rationale for investigating tirabrutinib for the treatment of patients with primary central nervous system lymphoma.

Susan O’Brien, MD

Latest:

Coordinating CLL Care to Identify BTKi Intolerance and Manage Toxicities

Panelists discuss how CLL treatment has evolved from universal single-agent BTKi use to personalized approaches based on patient risk factors like IGHV mutation status and TP53 mutations, with growing excitement about fixed-duration oral doublet therapies combining BTKis with venetoclax that show promising efficacy despite lower MRD rates compared with antibody-containing regimens, while addressing the management of BTKi class effects through dose-modification strategies that have become preferred over drug switching, emphasizing that intolerance is subjectively defined by patient acceptance and requires a multidisciplinary team approach including extensive patient education, close monitoring by nurses and pharmacists, and collaboration with cardio-oncology specialists to manage cardiovascular toxicities, with the notable exception that ventricular arrhythmias like PVCs warrant immediate consideration for drug discontinuation due to risk of sudden death.

Amado J. Zurita-Saavedra, MD

Latest:

Dr. Zurita-Saavedra on Augmenting Therapy Earlier in Prostate Cancer Treatment Journey

Amado J. Zurita-Saavedra, MD, discusses the potential benefits of augmenting therapy earlier on in the treatment of patients with newly diagnosed metastatic prostate cancer.

Virginia Kaklamani, MD

Latest:

Multidisciplinary Treatment Sequencing and Coordination

Panelists discuss their approach to sequencing surgery, radiation, and systemic therapies for early-stage breast cancer patients, emphasizing the guiding principles of treatment sequencing and how individual patient factors influence decisions; they also highlight the importance of multidisciplinary coordination, identifying key specialists, ensuring alignment on diagnosis, risk assessment, and treatment goals, and the critical role of including the patient in these discussions.

Isabella C. Glitza Oliva, MD, PhD, MS

Latest:

Dr. Glitza Olivia on the Potential Utility of Pembrolizumab/Selinexor in Advanced Melanoma

Isabella C. Glitza Oliva, MD, PhD, MS, discusses the potential utility of pembrolizumab in combination with selinexor in advanced melanoma.

Shridar Ganesan, MD, PhD

Latest:

Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care

Shridar Ganesan, MD, PhD, discusses the current limitations and advantages of leveraging circulating-tumor DNA to detect minimal residual disease in patients with cancer, as well as how ctDNA assays may address mechanisms of resistance in clinical practice.

Niloy Jewel J. Samadder, MD

Latest:

Examining the Promise of Multicancer Early Detection Tests: Looking to the Future

In this seventh episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, discuss the data that are still needed to inform optimal utilization of multicancer early detection tests and their potential cost effectiveness.

Vivek Subbiah, MD

Latest:

Key Takeaways and Future Perspectives for In-House Biomarker Testing

Panelists discuss how in this discussion the top 3 key points were patient-centric care, enhanced multidisciplinary coordination, and increased access and equity. In the next 3 to 5 years there will be more decentralized testing, potentially more practices participating in genomic profiling, the cost of testing will go down and the turnaround time will be shorter.

Conor Killmurray

Latest:

Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell Malignancies

Patients with B-cell malignancies who were intolerant to treatment with acalabrutinib experienced clinically meaningful benefits when treated with zanubrutinib, suggesting zanubrutinib may be a viable treatment option for this population.

Matthew Cortese, MD, MPH

Matthew Cortese, MD, MPH, is an assistant professor in the Department of Medicine–Lymphoma and Department of Cancer Genetics and Genomics at Roswell Park Comprehensive Cancer Center.

Latest:

Dr Cortese on Future Directions for the Multiomic Investigation of Venetoclax in CLL

Matthew Cortese, MD, MPH, discusses the next steps for the multiomic evaluation of venetoclax activity in chronic lymphocytic leukemia.

Natasha Kwendakwema, MD

Latest:

Dr Kwendakwema on the Effects of Financial Toxicity on Treatment Costs in Patients With Cancer

Natasha Kwendakwema, MD, discusses findings from a study on the effects of adverse financial events on treatment costs at the end of life and health care utilization in patients with cancer.

Marios Giannakis, MD, PhD

Latest:

Dr Giannakis on the Initial Efficacy of CGX1321 With or Without Pembrolizumab in GI Cancers

Marios Giannakis, MD, PhD, discusses preliminary efficacy data from a phase 1 study of CGX1321 with or without pembrolizumab in advanced gastrointestinal tumors.

Heather Moore, Pharm D

Latest:

Best Practices in Managing Patients on Capivasertib

Panelists discuss the key advice they would offer to fellow physicians, nurse practitioners, advanced practice providers, and pharmacists involved in the care of patients on capivasertib, emphasizing best practices for patient management and communication.

John Paul Diaz, MD

Diaz is the chief of Gynecologic Oncology, Robotic Surgery, and the Center of Excellence in Minimally Invasive Gynecologic Surgery at Baptist Health; as well as the lead physician for Clinical Trials in Gynecologic Oncology at Miami Cancer Institute, director of Ambulatory Surgery Center at Baptist Health Cancer Care | Plantation, and chair of the Department of Obstetrics and Gynecology at Florida International University Herbert Wertheim College of Medicine.

Latest:

Dr Diaz on the Importance of Early Recognition for Optimal Uterine Cancer Management

John P. Diaz, MD, discusses the importance of uterine cancer recognition and treatment optimization in the context of Gynecologic Cancer Awareness Month.

Ravi Munver, MD

Latest:

Dr. Munver on the Approval of Mitomycin Gel in Urothelial Cancer

Ravi Munver, MD, discusses the approval of mitomycin gel in urothelial cancer.

James K. McCloskey, MD, John Theurer Cancer Center

Latest:

The Future of Lower-Risk MDS: Closing Thoughts and Unmet Needs

Panelists discuss how community oncologists can apply key takeaways from this clinical scenario in their practice, emphasizing the importance of collaborating with academic clinicians for optimal patient identification and treatment selection in the evolving landscape of lower-risk MDS management.

Aditya Bardia, MD, MPH, FASCO

Aditya Bardia, MD, MPH, FASCO, is a professor in the Department of Medicine, Division of Hematology/Oncology and director of Translational Research Integration at UCLA Health Jonsson Comprehensive Cancer Center.

Latest:

Dr Bardia on the Importance of HER2 Testing in HER2-Expressing Breast Cancer

Aditya Bardia, MD, MPH, FASCO, discusses the need for widespread HER2 testing in patients with HER2-low and -ultralow metastatic breast cancer.